ABBV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ABBV is a strong long-term quality stock, but at the current price it is not the best immediate buy for a beginner investor who wants to deploy capital now and avoid waiting for a better entry. The trend is bullish, analyst sentiment is positive, and the business has solid growth drivers, but the stock is technically overbought after a sharp move. My direct view: hold off on a new full position today; it is acceptable only as a partial starter if you specifically want exposure now, but not a clear buy-at-any-price setup.
ABBV is in a clear uptrend: MACD histogram is positive and expanding, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price is trading above the pivot and has recently pushed toward resistance. However, RSI_6 at 84.363 signals the stock is overbought, which makes the current level extended rather than attractive for a fresh long-term entry. Key levels: support near 240.03 and 222.35, with resistance at 257.70 and 268.62. The recent move is strong, but momentum is stretched.
["Canaccord raised its price target to $273 and reiterated Buy after the Apogee acquisition, calling it strategically attractive.", "Piper Sandler remains Overweight and highlighted AbbVie's IBD pipeline and multiple R&D opportunities.", "Morgan Stanley stays Overweight and sees continued pipeline diversification as a key long-term driver.", "BofA upgraded ABBV to Buy, arguing immunology erosion fears are overdone and growth can last into the mid-2030s.", "News flow is supportive: Q1 2026 revenue was $15B, with major contributions from Skyrizi and Rinvoq.", "The Apogee Therapeutics acquisition should strengthen immunology exposure and support future growth."]
["RSI is extremely overbought, which reduces attractiveness for an immediate new entry.", "The stock has run up sharply in the regular session, making near-term upside less favorable from current levels.", "Some analysts still note competitive pressure concerns in immunology, especially around Skyrizi and the broader category.", "The Trump administration's proposed lower 340B hospital payment rates could pressure drug spending dynamics in the sector.", "Congress trading activity is mixed, with buying and selling relatively balanced rather than strongly bullish."]
Latest quarter shown: Q1 2026. AbbVie reported $15 billion in revenue, with strong contributions from Skyrizi and Rinvoq. That points to healthy underlying growth in the immunology franchise, which remains the key engine for the company. The news also suggests the company is using acquisitions and pipeline expansion to support growth beyond patent-risk areas. Overall, the latest quarter appears solid and growth-oriented.
Analyst sentiment is positive and has improved recently. Several firms maintained or raised bullish ratings: Canaccord upgraded its target to $273 and keeps Buy; Piper Sandler raised its target to $298 and keeps Overweight; Morgan Stanley raised its target to $278 and keeps Overweight; BofA upgraded to Buy with a $234 target. Evercore was slightly more cautious, trimming its target to $235 but still keeping Outperform. Wall Street pros are broadly constructive on AbbVie's immunology strength, pipeline depth, and long-term earnings durability, though some remain concerned about competition and post-2030 growth visibility. Recent target changes are generally upward, which is a positive sign.
